Ajit Banerjee expects fourth quarter to close the fiscal year on a firmer footing compared to the relatively softer first half. Overall earnings growth for FY26 is likely to be in the high single ...

The shift comes as Indian drugmakers increasingly pivot from a generics-led model toward innovative and specialty medicines that contribute a growing share of global revenues ...